NCT06887062View on ClinicalTrials.gov

Dual Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Large Vessel VasculitisGiant Cell Arteritis (GCA)Takayasu Arteritis
Interventions
DRUG

Bosentan

6 weeks of treatment with Bosentan, a dual endothelin receptor antagonist, administered to the large vessel vasculitis patient group

Trial Locations (1)

EH16 4TJ

RECRUITING

University of Edinburgh, Edinburgh

All Listed Sponsors
lead

University of Edinburgh

OTHER